Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -54.48% is 318% below its 5-year average of -13.02%, near the low end of its 5-year range (-54.48%–37.67%).
70.25% below its 12-month average of -32.00%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -12.38%.
RETURN ON ASSETS (ROA)
-54.48%
RETURN ON ASSETS (ROA) AVG TTM
-32.00%
RETURN ON ASSETS (ROA) AVG 3Y
-13.86%
RETURN ON ASSETS (ROA) AVG 5Y
-13.02%
RETURN ON ASSETS (ROA) AVG 10Y
-19.34%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-70.25%
CURRENT VS 3Y AVG
-293.00%
CURRENT VS 5Y AVG
-318.38%
CURRENT VS 10Y AVG
-181.70%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-68.85%
vs the sector median at left
Voyager Therapeutics, Inc.
Market Cap
$148.64M
Return on Assets (ROA)
-54.48%
TTM Avg
-32.00%
3Y Avg
-13.86%
5Y Avg
-13.02%
Market Cap
$148.73M
Return on Assets (ROA)
-96.78%
TTM Avg
-33.63%
3Y Avg
-87.61%
5Y Avg
-84.15%
Market Cap
$148.27M
Return on Assets (ROA)
-20.01%
TTM Avg
-38.20%
3Y Avg
-34.64%
5Y Avg
-39.69%
Market Cap
$149.36M
Return on Assets (ROA)
-50.30%
TTM Avg
-131.74%
3Y Avg
-92.52%
5Y Avg
-67.08%
Market Cap
$146.62M
Return on Assets (ROA)
-90.55%
TTM Avg
-70.80%
3Y Avg
-45.07%
5Y Avg
-40.08%
Market Cap
$146.28M
Return on Assets (ROA)
-25.59%
TTM Avg
-36.78%
3Y Avg
-35.70%
5Y Avg
-27.05%
Market Cap
$146.27M
Return on Assets (ROA)
35.31%
TTM Avg
-14.11%
3Y Avg
-23.46%
5Y Avg
-20.68%
Market Cap
$151.01M
Return on Assets (ROA)
-127.14%
TTM Avg
-129.15%
3Y Avg
-91.50%
5Y Avg
-82.73%
Market Cap
$152.72M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | $148.64M | -54.48% | -32.00% | -13.86% | -13.02% |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | -96.78% | -33.63% | -87.61% | -84.15% |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | -20.01% | -38.20% | -34.64% | -39.69% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | -50.30% | -131.74% | -92.52% | -67.08% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | -90.55% | -70.80% | -45.07% | -40.08% |
| Codexis, Inc. (CDXS)vs › | $146.28M | -25.59% | -36.78% | -35.70% | -27.05% |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | 35.31% | -14.11% | -23.46% | -20.68% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | -127.14% | -129.15% | -91.50% | -82.73% |
| Veraxa Biotech Holding AG (VRXA)vs › | $152.72M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | -76.12% | -156.63% | -142.29% | -134.64% |
ROA
-54.5%
ROE
-69.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -47.46% |
| 2024-12-31 | -16.54% |
| 2023-12-31 | 37.67% |
| 2022-12-31 | -29.12% |
| 2021-12-31 | -36.73% |
| 2020-12-31 | 14.05% |
| 2019-12-31 | -12.29% |
| 2018-12-31 | -49.87% |
| 2017-12-31 | -38.32% |
| 2016-12-31 | -21.20% |
| 2015-12-31 | -12.93% |
| 2014-12-31 | -141.92% |
| 2013-12-31 | -5144.97% |
